Takeaways From FDA's 1st Waiver Decision
On Feb. 22, 2013, the U.S. Food and Drug Administration approved two generic drugs with a risk evaluation and mitigation strategies (REMS) program that differed from the innovator company's existing REMS...To view the full article, register now.
Already a subscriber? Click here to view full article